Efficacy, safety and tolerability of cotadutide as an add-on therapy in overweight subjects with type 2 diabetes treated with dapagliflozin and metformin

被引：0
|
作者：
Flor, A. [1 ]
Petrone, M. [2 ]
Sanchez, J. [3 ]
Petrohoy, T. [4 ]
Jermutus, L. [2 ]
Hansen, L. [1 ]
Ambery, P. [3 ]
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] AstraZeneca, Cambridge, England
[3] AstraZeneca, Gothenburg, Sweden
[4] Pfizer, Collegeville, PA USA
来源：
DIABETOLOGIA | 2021年 / 64卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
476
引用
收藏
页码：247 / 247
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes
    Mueller-Wieland, Dirk
    Kellerer, Monika
    Cypryk, Katarzyna
    Skripova, Dasa
    Rohwedder, Katja
    Johnsson, Eva
    Garcia-Sanchez, Ricardo
    Kurlyandskaya, Raisa
    Sjostrom, C. David
    Jacob, Stephan
    Seufert, Jochen
    Dronamraju, Nalina
    Csomos, Katalin
    DIABETES OBESITY & METABOLISM, 2018, 20 (11): : 2598 - 2607
  • [2] Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus
    Pan, C.
    Xing, X.
    Han, P.
    Zheng, S.
    Ma, J.
    Liu, J.
    Lv, X.
    Lu, J.
    Bader, G.
    DIABETES OBESITY & METABOLISM, 2012, 14 (08): : 737 - 744
  • [3] Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes
    Matthaei, S.
    Bowering, K.
    Rohwedder, K.
    Sugg, J.
    Parikh, S.
    Johnsson, E.
    DIABETES OBESITY & METABOLISM, 2015, 17 (11): : 1075 - 1084
  • [4] Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes
    Mathieu, C.
    Herrera Marmolejo, M.
    Gonzalez Gonzalez, J. G.
    Hansen, L.
    Chen, H.
    Johnsson, E.
    Garcia-Sanchez, R.
    Iqbal, N.
    DIABETES OBESITY & METABOLISM, 2016, 18 (11): : 1134 - 1137
  • [5] Efficacy and safety of supaglutide as add-on to metformin in patients with type 2 diabetes
    Anwar, D.
    Bao, Y.
    Zhou, Y.
    Chen, S.
    Zhou, J.
    Li, L.
    Cheng, Z.
    Dong, X.
    Shi, X.
    Zhao, N.
    Yang, Y.
    Ma, J.
    Li, Y.
    Wang, Q.
    Jia, W.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S322 - S322
  • [6] Efficacy and Safety of Supaglutide as Add-on to Metformin in Patients with Type 2 Diabetes
    Anwar, Dilbar
    Bao, Yuqian
    Zhou, Yue
    Chen, Si
    Zhou, Jian
    Li, Liang
    Cheng, Zhifeng
    Dong, Xiaolin
    Shi, Xiaoxia
    Su, Xiuhai
    Li, Liping
    Wang, Haifang
    Wang, Yihua
    Li, Shu
    Li, Qingju
    Li, Xing
    Liu, Ming
    Sun, Jiao
    Zhao, Naiqing
    Yang, Yehong
    Ma, Jianhua
    Li, Yiming
    Wang, Qinghua
    Jia, Weiping
    DIABETES, 2023, 72
  • [7] DAPAGLIFLOZIN: COST EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES IN ECUADOR
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Sanchez, Solis C.
    Acosta, W.
    Solorzano, J.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2016, 19 (03) : A202 - A202
  • [8] Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes
    Duran-Garcia, S.
    Lee, J.
    Yki-Jarvinen, H.
    Rosenstock, J.
    Hehnke, U.
    Thiemann, S.
    Patel, S.
    Woerle, H. -J.
    DIABETIC MEDICINE, 2016, 33 (07) : 926 - 933
  • [9] Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in patients with type 2 diabetes
    Lee, J.
    Duran-Garcia, S.
    Yki-Jarvinen, H.
    Rosenstock, J.
    Hehnke, U.
    Thiemann, S.
    Patel, S.
    Woerle, H. -J.
    DIABETOLOGIA, 2013, 56 : S355 - S355
  • [10] Triple therapy with saxagliptin and dapagliflozin add-on to metformin: safety of dual add-on versus sequential add-on
    Garcia-Sanchez, R.
    Del Prato, S.
    Matthaei, S.
    Iqbal, N.
    Hansen, L.
    Johnsson, E.
    Chen, H.
    Chin, A. J.
    Mathieu, C.
    DIABETOLOGIA, 2015, 58 : S356 - S356
12345